|Table of Contents|

Analysis of laboratory and clinical characteristics of treatment-related acute myeloid leukemia（40 cases）

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3081-3085
Research Field:
Publishing date:

Info

Title:
Analysis of laboratory and clinical characteristics of treatment-related acute myeloid leukemia（40 cases）
Author(s):
JIANG Yanhong1; JIAO Yang1; WANG Hao1; BI Lijun2; XU Qingxia1
1.Department of Clinical Laboratory,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou Key Laboratory of Digestive Tumor Markers,Henan Zhengzhou 450008,China;2.Institute of Biophysics,Chinese Academy of Scineces,Guangdong Foshan 528000,China.
Keywords:
treatment-related; acute myeloid leukemia; cross-lineage antigen expression; genetic mutation
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2023.16.026
Abstract:
Objective:To analyze the abnormal expression of lymphoid antigen and other laboratory and clinical features in 40 patients with treatment-related acute myeloid leukemia(t-AML).Methods:To retrospectively analyze the laboratory and clinical data of 40 patients with t-AML in our hospital from January 2014 to December 2021.The laboratory and clinical data were obtained by consulting the electronic medical record system and laboratory data management system.SPSS 25.0 software was used for data analysis.Results:The median interval from the first tumor to t-AML in 40 patients was 21(16~41) months.24(60.0%) had abnormal expression of lymphoid antigen,27(67.5%) had abnormal karyotype,18 cases (45.0%) were positive for fusion gene,and 27 cases (67.5%) were positive for gene mutation.The median RFS was 11.0(1.0～79.0)months,and the median OS was 11.5(1.0～80.0)months.Conclusion:Compared with previous reports in the literature on primary AML,t-AML patients have a high proportion of cross-lineage antigen expression and a high proportion of gene mutations.

References:

［1］袁芳芳,尹青松,李梦娟,等.8例淋巴瘤继发急性髓系白血病的临床病理特征及疗效［J］.中华肿瘤杂志,2019,41(7):533-534. YUAN FF,YIN QS,LI MJ,et al.The clinical pathological features and therapeutic effects of 8 cases of lymphoma treat-related acute myeloid leukemia［J］.Chinese Journal of Oncology,2019,41(7):533-534.
［2］KHOURY JD,SOLARY E,ABLA O,et al.The 5th edition of the World Health Organization classification of haematolymphoid tumours:Myeloid and histiocytic/dendritic neoplasms［J］.Leukemia,2022,36(7):1703-1719.
［3］KOTSIAFTI A,GIANNAKAS K,CHRISTOFOROU P,et al.Progress toward better treatment of therapy-related AML［J］.Cancers (Basel),2023,15(6):1658.
［4］KAPLAN HG,MALMGREN JA.Leukemia incidence following primary breast carcinoma treatment［J］.Cancer,2004,101(7):1529-1536.
［5］KAYSER S,DOHNER K,KRAUTER J,et al.The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML［J］.Blood,2011,117(7):2137-2145.
［6］卢绮思,许娜,周璇,等.35例治疗相关血液肿瘤患者的临床特征及预后分析［J］.中华血液学杂志,2016,37(3):221-226. LU QS,XU N,ZHOU X,et al.Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms［J］.Chinese Journal of Hematology,2016,37(3):221-226.
［7］林冬,张广吉,秘营昌,等.t(8;21)急性髓系白血病治疗后继发治疗相关性骨髓增生异常综合征一例报告并文献复习［J］.中华血液学杂志,2018,39(1):50-52. LIN D,ZHANG GJ,MI YC,et al.Secondary myelodysplastic syndrome in a patient with de novo t(8;21) acute myeloid leukemia:a case report and literatures［J］.Chinese Journal of Hematology,2018,39(1):50-52.
［8］ZHANG L,WANG SA.A focused review of hematopoietic neoplasms occurring in the therapy-related setting［J］.Int J Clin Exp Pathol,2014,7(7):3512-3523.
［9］CALIP GS,MALMGREN JA,LEE WJ,et al.Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer［J］.Breast Cancer Res Treat,2015,154(1):133-143.
［10］王晚霞.淋系抗原表达在评判急性髓系白血病预后中的价值［D］.郑州：新乡医学院,2020. WANG WX.Value of lymphocytic antigen expression in evaluating the prognosis of acute myeloid leukemia［D］.Zhengzhou:Xinxiang Medical University,2020.
［11］梁建英,马勤芬,朱明清,等.伴淋系抗原表达的急性髓系白血病的临床及MIC分型特征［J］.中华血液学杂志,2007,28(11):776-777. LIANG JY,MA QF,ZHU MQ,et al.Clinical and MIC typing characteristics of acute myeloid leukemia with antigen expression［J］.Chinese Journal of Hematology,2007,28(11):776-777.
［12］王婧婧，王超，闰晓爽，等.188 例急性髓系白血病 M2 型患者的临床特征及预后分析［J］.中国实验血液学杂志，2019，27（5）：1360-1366. WANG JJ,WANG C,RUN XS,et al.Clinical features and prognosis of 188 patients with acute myeloid leukemia M2［J］.Journal of Experimental Hematology，2019，27（5）：1360-1366.
［13］MCNERNEY ME,GODLEY LA,LE BEAU MM.Therapy-related myeloid neoplasms:when genetics and environment collide［J］.Nat Rev Cancer，2017，17(9):513-527.
［14］OK CY,PATEL KP,GARCIA-MANERO G,et al.Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing,a comparison with de novo diseases［J］.Leuk Res,2015,39(3):348-354.
［15］CHURPEK JE,MARQUEZ R,NEISTADT B,et al.Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia［J］.Cancer,2016,122(2):304-311.
［16］WOLFF AC,BLACKFORD AL,VISVANATHAN K,et al.Risk of marrow neoplasms after adjuvant breast cancer therapy:the national comprehensive cancer network experience［J］.J Clin Oncol,2015,33(4):340-348.
［17］DOHNER H,ESTEY EH,AMADORI S,et al.Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel,on behalf of the European LeukemiaNet［J］.Blood,2010,115(3):453-474.
［18］TAKAHASHI K.Germline polymorphisms and the risk of therapy-related myeloid neoplasms［J］.Best Pract Res Clin Haematol,2019,32(1):24-30.
［19］DOHNER H,ESTEY E,GRIMWADE D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel［J］.Blood,2017,129(4):424-447.
［20］FELDMAN EJ.Does therapy-related AML have a poor prognosis,independent of the cytogenetic/molecular determinants［J］.Best Pract Res Clin Haematol,2011,24(4):523-526.
［21］SCHOCH C,KERN W,SCHNITTGER S,et al.Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML):an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML［J］.Leukemia,2004,18(1):120-125.

Memo

Memo:
National Natural Science Foundation of China(No.82203572);国家自然科学基金项目（编号：82203572）
Last Update: 1900-01-01